Summary & Overview
HCPCS J0597: c-1 Esterase Inhibitor (Berinert) Injection, 10 Units
HCPCS Level II code J0597 denotes the injectable biologic c-1 esterase inhibitor (human), Berinert, 10 units, used primarily for treatment of hereditary angioedema and related indications. Nationally, this code is important for accurate capture of high-cost biologic therapy administered in outpatient infusion and office-based settings, affecting coverage, prior authorization, and specialty pharmacy coordination.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings, payer coverage patterns, reimbursement benchmarks, and common billing considerations relevant to institutional and professional claims. The publication outlines coding nuances for HCPCS Level II code J0597, typical sites of service, and implications for claims processing and utilization management.
This summary equips billing managers, revenue cycle leaders, and clinical program directors with the information needed to align billing workflows and payer communications for administration of J0597. Data not available in the input are noted where applicable; the report focuses on national-level considerations rather than state-specific policy.
Billing Code Overview
HCPCS Level II code J0597 represents the injection of c-1 esterase inhibitor (human), Berinert, 10 units. This HCPCS Level II code captures a biologic replacement therapy used for treatment of hereditary angioedema (HAE) and other indicated uses for C1 esterase inhibitor replacement.
Service Type: Injectable biologic therapy
Typical Site of Service: Outpatient infusion or injection setting, including ambulatory infusion centers, hospital outpatient departments, and physician offices equipped for parenteral biologic administration.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with hereditary angioedema (HAE) presenting to an outpatient infusion center, emergency department, or hospital for on-demand treatment of an acute angioedema attack or for short-term prophylaxis prior to a triggering procedure. The patient reports progressive, nonpitting swelling of the face, tongue, or extremity, or severe abdominal pain with vomiting. After clinician assessment confirming HAE-related swelling or high suspicion for C1 esterase inhibitor deficiency, the ordered product J0597 (berinert, human C1 esterase inhibitor, 10 units vial) is retrieved from pharmacy. A trained registered nurse or infusion pharmacist reconstitutes the product per manufacturer instructions and administers intravenous infusion through a peripheral IV. Vital signs and airway assessment are monitored before, during, and after administration. If given in the emergency department or inpatient setting, the medication is documented in the medication administration record and the dose is billed per vial using J0597. For prophylaxis prior to procedures (for example, dental extraction or surgery), the dose is given within the recommended window pre-procedure and documented with appropriate procedure notes and diagnosis linkage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier specified (default) |